Building upon the preliminary confirmation that Metformin targets the protein CA9, we further conducted in vitro validation experiments using liver cancer cells to evaluate the therapeutic effects of Metformin alone and in combination with Lenvatinib on liver cancer. The gene discussed is CA9; the disease is liver cancer.